Johnson & Johnson Units to Pay $65M Tracleer Antitrust Settlement; FDA Approves Myeloma Combo
Johnson & Johnson’s Actelion and Janssen units agreed to a $65 million settlement of an antitrust suit over Tracleer, pending court approval. The FDA approved TECVAYLI plus DARZALEX FASPRO for relapsed or refractory multiple myeloma after at least one prior therapy, extending J&J’s oncology pipeline.
1. Settlement Agreement
Johnson & Johnson’s Actelion and Janssen Research & Development units agreed to pay $65 million to resolve a proposed antitrust class action alleging they delayed generic competition for the pulmonary hypertension drug Tracleer by obstructing sample access. The preliminary settlement requires federal court approval in Maryland before becoming final.
2. FDA Approval of Myeloma Combo
The FDA approved the combination of TECVAYLI and DARZALEX FASPRO for adults with relapsed or refractory multiple myeloma after at least one prior therapy. The duo’s synergistic mechanism targets BCMA-expressing myeloma cells and could establish a new second-line treatment standard.
3. Analyst Outlook
JPMorgan raised its price target on Johnson & Johnson shares to $250 from $225, citing stronger-than-expected Tremfya performance in inflammatory bowel disease. The revision reflects heightened optimism about the company’s growth prospects in its immunology and oncology segments.